Expression Of IMP2 In Glioma And Its Clinical Significance

Objective: To study the feasibility of IMP2 as a biomarker for glioma,and to explore the clinical significance of IMP2 in the treatment of glioma patients.Methods: 1.From September 2016 to December 2018,the fresh tumor tissue and paraneoplastic tissues of patients with glioma diagnosed by neurosurgery in the First Hospital of Jilin University were collected,and the blood of the patients who was initially diagnosed as glioma by the imaging diagnosis was collected.From the radiology department of the First Hospital of Jilin University,the blood of the glioma patients after surgery and first course of radiotherapy was collected;the blood of normal healthy people was collected.2.The collected fresh tissue was made into paraffin sections and extracted with tissue protein.The collected blood was centrifuged to collect plasma,and stored at-80 ° C.3.Immunohistochemistry and Western Blot were used to detect the expression of IMP2 protein in glioma tissues and paraneoplastic tissues.4.ELISA and Western Blot were used to detect the expression of IMP2-Ab in glioma preoperative patients,glioma postoperative radiotherapy patients and normal human plasma.5.Collect the clinical data of glioma patients,and analyze the correlation between IMP2 and clinical data by statistical methods.Results: 1.Immunohistochemistry showed that among the 58 glioma tissue sections,47 cases were positive for IMP2 protein,and the positive rate was 81.0%.Among the 58 cases with glioma tissue sections,13 cases were positive for IMP2 protein,and the positive rate was 22.4%.Using chi-square test,the difference between the two groups was statistically significant(P<0.05),that is,the expression of IMP2 protein in glioma tissues was significantly higher than that in paraneoplastic tissues.2.Organize the results of immunohistochemistry and clinical data of patients,and further analyze the relationship between IMP2 protein expression and clinical pathological data of glioma.The results showed that the expression of IMP2 protein was not related to the age,sex or tumor pathological type of the patient,but was significantly correlated with tumor size and WHO classification.Among them,the positive rate of IMP2 protein in glioma patients with tumor diameter less than 3cm was 57.1%,and the positive rate of IMP2 protein in glioma patients with tumor diameter greater than 3cm was 94.6%.The difference between the two groups was statistically significant(P<0.05);the positive rate of IMP2 protein in patients with low-grade glioma(WHO I-II)was 78.9%,and the positive rate of IMP2 protein in high-grade glioma(WHO III-IV)patients was 87.8%.The difference was statistically significant(P < 0.05).At the same time,the expression of IMP2 protein in different grades of glioma patients was detected by western-blot.The statistical analysis of the gray value of the bands showed significant difference(P<0.05),that is,the more expression of IMP2 protein in glioma,the higher the WHO classification.3.ELISA results showed that in the 45 patients with glioma,17 cases of IMP2-Ab were positive in the plasma,the positive rate was 37.8%;25 cases of glioma postoperative radiotherapy in 5 patients with IMP2-Ab positive,the positive rate 20.0%;1 of 24 normal human plasma was found to be IMP2-Ab positive,with a positive rate of 4.2%.Using chi-square test,the difference between the three groups of data was statistically significant(P<0.05),that is,the expression of IMP2-Ab in glioma patients,glioma postoperative radiotherapy patients and normal human plasma was different.4.Further statistical analysis showed that the expression of IMP2-Ab in the blood of patients with glioma.The difference between the normal people was statistically significant,that is,the expression of IMP2-Ab in the blood of patients with glioma was significantly higher than that of normal people(P<0.0166).However,there was no significant difference in the expression of IMP2-Ab in the blood of glioma preoperative patients and postoperative radiotherapy patients,glioma postoperative radiotherapy patients and normal people.5.Organize the results of ELISA and clinical data of patients to further analyze the relationship between the expression of IMP2-Ab in plasma and clinical pathological data of glioma patients.The results showed that the expression of IMP2-Ab was not related to the age,sex or tumor size and pathological type of the patient,but was significantly correlated with the WHO classification.The positive rate of IMP2-Ab in plasma of patients with low-grade glioma(WHO I-II)was 7.7%,and the positive rate of IMP2-Ab in plasma of patients with high-grade glioma(WHO III-IV)was 50.0%.The difference was statistically significant(P < 0.05).Conclusion: 1.The expression of IMP2 protein in glioma tissues is significantly higher than that in paraneoplastic tissues.The expression of IMP2 protein is significantly correlated with tumor volume and WHO level,indicating that IMP2 protein contributes to the diagnosis of glioma,and the higher the expression of IMP2 protein,the more the tumor volume is predicted.Large,the higher the WHO level.2.The expression of IMP2-Ab in the blood of patients with glioma before surgery was significantly higher than that of normal people,and its expression was significantly correlated with WHO grade,but there was no significant difference between postoperative radiotherapy patients and normal subjects.This indicates that IMP2-Ab contributes to the initial diagnosis and efficacy monitoring of glioma patients,and the higher the expression of IMP2-Ab indicates the higher the WHO level.